Alembic Pharmaceuticals
Alembic Pharmaceuticals Limited, commonly referred to as Alembic, is a prominent player in the global pharmaceutical industry, headquartered in Vadodara, India. Established in 1907, the company has a rich history marked by significant milestones, including its expansion into regulated markets and the development of a robust portfolio of generic and branded formulations. Alembic operates primarily in the areas of pharmaceuticals, biotechnology, and active pharmaceutical ingredients (APIs), focusing on therapeutic segments such as cardiovascular, anti-infective, and central nervous system disorders. The company is renowned for its commitment to quality and innovation, which is reflected in its extensive range of products that meet stringent international standards. With a strong market position, Alembic Pharmaceuticals has achieved notable success, including multiple approvals from regulatory authorities worldwide. Its dedication to research and development, coupled with a strategic approach to global expansion, solidifies its reputation as a trusted name in the pharmaceutical sector.
DitchCarbon Score
How does Alembic Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alembic Pharmaceuticals's score of 55 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Alembic Pharmaceuticals's reported carbon emissions
In 2024, Alembic Pharmaceuticals reported total greenhouse gas emissions of approximately 86096000 kg CO2e for Scope 1, 67544000 kg CO2e for Scope 2, and a significant 756174000 kg CO2e for Scope 3 emissions. This reflects a comprehensive approach to emissions reporting, covering all three scopes. The company has set ambitious targets to reduce its greenhouse gas emissions, aiming for a 63% reduction by 2035 and a net-zero commitment by 2050, based on a 2022 baseline. In 2023, the emissions were recorded at 79194000 kg CO2e for Scope 1, 83482000 kg CO2e for Scope 2, and 644996000 kg CO2e for Scope 3. The total emissions for that year were approximately 807672000 kg CO2e, indicating a proactive stance towards sustainability. Alembic Pharmaceuticals has committed to reducing absolute Scope 1, 2, and 3 emissions by 63% by FY2034 and aims for a long-term reduction of 90% by FY2050. These targets are aligned with the Science Based Targets initiative (SBTi) and are designed to keep global warming below 1.5°C. The company’s efforts reflect a strong commitment to environmental responsibility within the pharmaceutical sector, positioning itself as a leader in climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | - | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Alembic Pharmaceuticals is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
